Trials / Completed
CompletedNCT05359068
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 957 (actual)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPH3127 tablet | 1 tablet |
| DRUG | SPH3127 tablet | 2 tablets |
| DRUG | SPH3127 tablet | 4 tablets |
| DRUG | Valsartan | 1 valsartan capsule |
| DRUG | SPH3127 tablet | 2 tablets |
| DRUG | Valsartan | 1 valsartan capsule |
Timeline
- Start date
- 2021-06-10
- Primary completion
- 2023-12-26
- Completion
- 2023-12-26
- First posted
- 2022-05-03
- Last updated
- 2024-05-07
Locations
40 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05359068. Inclusion in this directory is not an endorsement.